Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021)

Stoke Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $66.0 million for Q4 2021.

• In Q4 2021, Long-Term Deferred Tax rose 77.42% year-over-year to $66.0 million; the TTM figure through Dec 2021 stood at $66.0 million (up 77.42% YoY), while the FY2021 annual figure was $66.0 million, up 77.42% from the prior year.
• Long-Term Deferred Tax was $66.0 million for Q4 2021 at Stoke Therapeutics, up from $37.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $66.0 million in Q4 2021 to a low of $7.6 million in Q4 2018.
• Historically, Long-Term Deferred Tax has averaged $32.2 million across 4 years, with a median of $27.6 million in 2019.
• The sharpest annual moves came in 2019 and 2021: Long-Term Deferred Tax surged 135.53% in 2019, then surged 77.42% in 2021.
• A 4-year view of Long-Term Deferred Tax shows it stood at $7.6 million in 2018, then jumped by 135.53% to $17.9 million in 2019, then surged by 107.82% to $37.2 million in 2020, then soared by 77.42% to $66.0 million in 2021.
• The last three Long-Term Deferred Tax figures came in at $66.0 million (Q4 2021), $37.2 million (Q4 2020), and $17.9 million (Q4 2019), per Business Quant data.